Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xolair Pediatric Efficacy Discussion Slides Into Value Of Treatment

Executive Summary

FDA's attempt to describe its internal assessment of "relatively modest" efficacy from the pediatric use of Novartis/Genentech's Xolair (omalizumab) during the Nov. 18 joint meeting of the Pulmonary & Allergy and Pediatric Drugs Advisory Committee opened up parts of the meeting to questions generally beyond the purview of regulatory decisions
Advertisement

Related Content

Novartis Pediatric Post-Market Plans For Xolair Fall Short Of FDA Request
Novartis Pediatric Post-Market Plans For Xolair Fall Short Of FDA Request

Topics

Advertisement
UsernamePublicRestriction

Register

PS051724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel